Señales en vivo de 4147.TWO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 01:30):

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases...

Stats
Volumen de hoy	499 686
Volumen promedio	2.40M
Capitalización de mercado	21.00B
EPS	TWD0 ( 2024-03-11 )
Próxima fecha de ganancias	( TWD0 ) 2024-05-08
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-109.21
ATR14	TWD0.0670 (0.08%)

Volumen Correlación

Largo: -0.07 (neutral)

Corto: -0.84 (strong negative)

Signal:(43.984) Neutral

TaiMed Biologics Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TaiMed Biologics Inc. Correlación - Moneda/Commodity

0.43
( neutral )

0.51
( weak )

0.00
( neutral )

0.52
( weak )

0.31
( neutral )

-0.45
( neutral )

TaiMed Biologics Inc. Finanzas

Annual	2023
Ingresos:	TWD491.78M
Beneficio Bruto:	TWD225.23M (45.80 %)
EPS:	TWD-0.760

FY	2023
Ingresos:	TWD491.78M
Beneficio Bruto:	TWD225.23M (45.80 %)
EPS:	TWD-0.760

FY	2022
Ingresos:	TWD563.01M
Beneficio Bruto:	TWD215.71M (38.31 %)
EPS:	TWD-1.090

FY	2021
Ingresos:	TWD413.44M
Beneficio Bruto:	TWD83.96M (20.31 %)
EPS:	TWD-1.867

Financial Reports:

No articles found.

TaiMed Biologics Inc.

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.